»您现在的位置: 第一至尊娱乐平台网 >> 至尊娱乐平台焦点 >> 文传商讯 >> 正文

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

2019/9/4 16:41:33  文章来源:文传商讯  作者:文传商讯
文章简介: ThedualactingGLP-1/glucagonpeptideBI456906isapartofBoehringerIngelheim’spipelineportfolioinobesityanddiabetes ThePhase2trialforBI456906i

The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim’s pipeline portfolio in obesity and diabetes
The Phase 2 trial for BI 456906 is expected to be initiated in late 2019 and will trigger a EUR 20 million milestone payment to Zealand Pharma out of total outstanding potential milestone payments of EUR 365 million and high single to low double digit royalties on future sales

INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand’s expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases.

The compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has potential as a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.1 It is part of Boehringer Ingelheim’s growing research and development stage portfolio in the obesity and diabetes disease areas.

The decision to advance BI 456906 to Phase 2 clinical testing is based on the safety and tolerability and the favorable weight loss potential in individuals with a BMI up to 40 kg/m2. The Phase 2 trial will be a dose-finding, placebo and active comparator clinical proof of concept trial in patients with obesity and type 2 diabetes.

“We believe that BI 456906 has great therapeutic potential, and we are thrilled to see it advance into Phase 2 development,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Our strong partnership with Boehringer Ingelheim unites expertise and capabilities to achieve a shared vision of helping millions of people better manage and overcome obesity and type 2 diabetes.”

“We are excited to see this candidate from our dedicated and productive long-term collaboration with Zealand Pharma proceed to the next stage of clinical studies,” explained Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This brings us an important step further to bringing BI 456906 to the many patients that are in need of new treatment options.”

Zealand has licensed two product candidates to Boehringer Ingelheim, both with potential for once-weekly administration. Under the terms of the two agreements, Boehringer Ingelheim funds all research, development and commercialization activities. For the GLP1/glucagon dual agonist, Zealand is entitled to receive up to EUR 365 million in outstanding milestone payments and will receive a milestone payment of EUR 20 million related to initiation of Phase 2. The agreement also carries high-single digit to low-double digit percentage royalties on global sales. The other collaboration compound is a long-acting amylin analog for which Zealand is entitled to receive up to EUR 283 million in outstanding milestone payments, and mid-single digit to low-double digit percentage royalties on global sales.

Excessive weight and obesity are amongst the leading risk factors for heart disease, ischemic stroke, liver diseases and type 2 diabetes as well as for a number of cancers. There are insufficient therapeutic options available, resulting in a high unmet medical need for safe and effective treatments that achieve significant weight loss. Boehringer Ingelheim’s track record of excellence in research and development in cardiometabolic diseases is evidence of its innovation which has resulted in important breakthroughs in recent years, especially in thromboembolic diseases and type 2 diabetes.

Please click on the following link for ‘Notes to Editors’ and ‘References’:


2、文章来源为均为其它ag亚游网址的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供环亚ag信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。

 姓 名:
 评 分: 1分 2分 3分 4分 5分
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及皇家国际娱乐平台人民其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏真钱百人牛牛稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  至尊娱乐男篮生死战是怎么回事?至尊娱乐男篮生死战具体
    [银行]  银行怎么了?六大银行上半年减员近3.5万人
    [股票]  200亿"福布斯富豪"彻底凉了?公司美女总裁称病不
     暴风集团冯鑫事件 其多家企业为失信公司
    [基金]  2019年赚钱的公募基金都有谁 2019年赚钱基金排名
     大盘重回3000点 大涨底气在哪?基金最新解读来了
    [保险]  人保车险理赔时间规定
    [期货]  油价调整蕞新消息:9月3日24时 本轮成品油上调板
     消息人士:至尊娱乐考虑大幅放开期货市场 以吸引海外
    [股评]  六大券商周四看好六大板块(9/5)
     券商评级:三大指数上涨 九股迎来掘金良机(9/5
    [港股]  小米120亿回购引争议:现金流承压 谁在抛售谁被
     No zuo no die!国泰航空19天蒸发超百亿,遭强烈
    [美股]  苹果2019年秋季发布会什么时候 相关产业链概念股
     百度广告困境:代理商无奈 广告主逃离
    [至尊娱乐平台登录]  突发!美元兑人民币逼近7.2!触及7.18345
     人民币对美元汇率中间价报7.0211元 下调75个基点
    [债券]  乐投体育超越至尊娱乐 成美债最大海外持有国
     中城集团旗下多支债券违约 14亿银行存款被冻结
    [黄金]  黄金疯涨!六年前血战华尔街的“至尊娱乐大妈”解套
    [理财]  建国70周年币什么时候发行 2019建国70周年纪念币
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [房产]  2019年下半年房价走势会如何?房价会跌吗?
     至尊娱乐房企海外融资大幅缩水 环比下跌近八成
    [汽车]  特斯拉App宕机是怎么回事?至尊娱乐特斯拉App宕机事
  • 此栏目下没有推荐文章
  • | 设为至尊娱乐 | 加入收藏 | 关于我们 | ag捕鱼 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版权所有·第一至尊娱乐平台网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!



    合作邮箱:鼎盛娱乐 合作电话:环亚ag 点击这里给我发消息